argenx SE
Develops and commercializes antibody-based therapies for severe autoimmune diseases.
1AE | BR
Overview
Corporate Details
- ISIN(s):
- NL0010832176 (+1 more)
- LEI:
- 7245009C5FZE6G9ODQ71
- Country:
- Netherlands
- Address:
- Laarderhoogtweg 25, 1101EB Amsterdam
- Website:
- https://www.argenx.com/?allow=1
- Sector:
- Manufacturing
Description
argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-06-04 08:15 |
argenx to Present at Goldman Sachs 41st Annual Global Healthcare Conference
|
English | 26.8 KB | ||
| 2020-06-02 08:09 |
argenx announces closing of global offering
|
English | 38.6 KB | ||
| 2020-05-29 07:56 |
argenx announces full exercise of underwriters’ option to purchase additional A…
|
English | 48.3 KB | ||
| 2020-05-28 08:42 |
argenx raises $750 million in gross proceeds in a global offering
|
English | 60.8 KB | ||
| 2020-05-27 08:16 |
argenx announces launch of proposed global offering
|
English | 62.3 KB | ||
| 2020-05-26 08:17 |
argenx Announces Positive Topline Results from Phase 3 ADAPT Trial of Efgartigi…
|
English | 120.3 KB | ||
| 2020-05-14 08:28 |
argenx reports first quarter 2020 financial results and provides business update
|
English | 125.5 KB | ||
| 2020-05-12 14:32 |
argenx announces results of Annual General Meeting of Shareholders
|
English | 33.5 KB | ||
| 2020-05-08 12:00 |
argenx to Present Data from Phase 2 Trial of Efgartigimod in Pemphigus at 2020 …
|
English | 34.6 KB | ||
| 2020-05-07 08:33 |
argenx to report first quarter 2020 financial results and business update on Ma…
|
English | 34.3 KB | ||
| 2020-05-06 08:33 |
argenx to Present at BofA Securities Virtual Health Care Conference 2020
|
English | 26.9 KB | ||
| 2020-04-29 09:34 | English | 4.2 MB | |||
| 2020-03-31 09:00 |
argenx announces Annual General Meeting of Shareholders on May 12, 2020
|
English | 37.0 KB | ||
| 2020-02-27 08:26 |
argenx reports full year 2019 financial results and provides fourth quarter bus…
|
English | 347.0 KB | ||
| 2020-02-27 08:26 |
argenx reports full year 2019 financial results and provides fourth quarter bus…
|
English | 127.2 KB |
Automate Your Workflow. Get a real-time feed of all argenx SE filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for argenx SE
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for argenx SE via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
